Product Overview

Semi Daonil 2.5 mg is a prescription medication manufactured by Sanofi India Limited that contains the active ingredient glibenclamide. It is classified under the therapeutic category of Diabetes Care and is specifically indicated for the management of Type 2 diabetes mellitus. The product is supplied in a convenient strip containing ten tablets, each delivering a precise 2.5 mg dose of glibenclamide. Pack size options include 60, 90, and 120 tablets, allowing patients and healthcare providers to select the most appropriate quantity for ongoing treatment. Delivery typically occurs within 6 to 15 days after order placement, ensuring a reliable supply chain for chronic disease management.

What is Semi Daonil 2.5 mg (Glibenclamide)

Glibenclamide, also known as glyburide in some regions, belongs to the sulfonylurea class of antidiabetic agents. It functions by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels in patients with Type 2 diabetes. Semi Daonil is formulated as a tablet strengths of 2.5 mg, providing a consistent therapeutic effect when used as directed. The medication is marketed by Sanofi India Limited, a reputable pharmaceutical company with a longstanding presence in the Indian market. Its pharmacological profile has been extensively studied and documented in resources such as the NIH’s PubChem database and the FDA’s drug label repository.

Uses and Benefits

The primary use of Semi Daonil 2.5 mg is to improve glycemic control in adults with Type 2 diabetes who have not achieved adequate glucose regulation through diet and exercise alone. When incorporated into a comprehensive treatment plan, glibenclamide can help reduce fasting and postprandial glucose concentrations, thereby decreasing the risk of diabetes‑related complications such as cardiovascular disease, nephropathy, and retinopathy. Additional benefits include a straightforward dosing regimen, cost‑effectiveness compared with some newer antidiabetic agents, and the availability of multiple pack sizes to suit individual patient needs. Clinicians often consider glibenclamide when patients require a proven, well‑understood therapy with a long history of clinical experience.

How It Works

Glibenclamide exerts its antidiabetic effect by binding to the ATP‑sensitive potassium channel on the surface of pancreatic beta cells. This binding leads to closure of the channel, depolarization of the cell membrane, and subsequent influx of calcium ions, which triggers insulin secretion. The released insulin enhances peripheral glucose uptake and suppresses hepatic glucose production, resulting in a net reduction of circulating blood glucose. The onset of action typically occurs within one to two hours after oral administration, with peak effects observed around 2 to 3 hours post‑dose. Understanding this mechanism assists healthcare providers in setting realistic expectations for blood sugar lowering and in monitoring patients for potential hypoglycemia, especially during the early phases of therapy.

Dosage Guidelines

Dosage of Semi Daonil must always be individualized by a qualified healthcare professional based on the patient’s renal function, concomitant medications, and overall health status. The usual starting dose is one tablet (2.5 mg) taken orally once daily, which may be adjusted upward in increments of 1.25 mg to 2.5 mg at intervals of 1 to 2 weeks, depending on glycemic response and tolerability. It is crucial that patients do not self‑adjust the dose without medical supervision, as inappropriate dosing can increase the risk of hypoglycemia. Tablets should be swallowed whole with water and can be taken with or without food, although consistent timing each day helps maintain steady drug levels. For patients with moderate to severe renal impairment, dose reduction is recommended to avoid drug accumulation.

Side Effects

Like all medications, Semi Daonil 2.5 mg may cause adverse effects, although not everyone experiences them. The most commonly reported side effects include hypoglycemia, dizziness, headache, nausea, and mild skin rash. Less frequent but clinically important reactions comprise hepatic enzyme elevations, Stevens‑Johnson syndrome, and severe hypersensitivity responses. Patients should be instructed to seek immediate medical attention if they experience signs of severe hypoglycemia such as confusion, excessive sweating, or loss of consciousness, or if they develop any dermatologic reactions that spread rapidly. Regular laboratory monitoring of liver function and renal parameters is advisable during long‑term therapy.

Warnings and Precautions

Semi Daonil is contraindicated in individuals with a known hypersensitivity to glibenclamide or any component of the formulation, as well as in patients with Type 1 diabetes, diabetic ketoacidosis, or a history of allergic reactions to sulfonylureas. Caution is advised in patients with severe hepatic disease, adrenal or pituitary insufficiency, or those undergoing surgery, as these conditions may alter drug metabolism. Concomitant use with certain medications such as certain antibiotics, antifungals, or non‑steroidal anti‑inflammatory drugs can potentiate hypoglycemic effects, necessitating dose adjustments. Pregnant and breastfeeding women should only use the medication under the guidance of a physician, and routine blood glucose monitoring is essential to avoid maternal and fetal complications. Proper storage at room temperature, away from moisture and heat, preserves tablet integrity.

Frequently Asked Questions

1. What is the difference between glibenclamide and glyburide? While glibenclamide and glyburide are chemically similar sulfonylureas, glyburide is the United States adopted name for the same active ingredient. In some markets, the term glyburide is used interchangeably with glibenclamide, but the dosage and formulation may vary slightly.
2. Can Semi Daonil be used alongside insulin therapy? Yes, glibenclamide may be combined with insulin in certain clinical scenarios, but this combination increases the risk of hypoglycemia. Such regimens should only be undertaken under close medical supervision with frequent glucose monitoring.
3. How should I store the medication? Store Semi Daonil tablets in their original packaging at room temperature, away from direct sunlight and moisture. Keep the strip sealed until ready to use, and do not refrigerate unless advised by a healthcare professional.
4. Is weight gain a common side effect? Weight gain can occur with some antidiabetic agents, including sulfonylureas, due to improved glucose control and increased appetite. However, the effect is generally modest and can be managed through diet and physical activity.
5. Where can I find more detailed prescribing information? Comprehensive prescribing details are available on authoritative sites such as the FDA’s drug label database (FDA), MedlinePlus (MedlinePlus), and Drugs.com (Drugs.com).

For additional clinical guidance, healthcare professionals may refer to the National Institutes of Health’s resource on antidiabetic agents (NIH) and the European Medicines Agency’s assessment reports.

Related Products

• Allegra (Fexofenadine)
• Fexofenadine 30 Mg (Generic)
• Fexofenadine 120 Mg (Generic)
• Fexofenadine 180 Mg (Generic)
• Allegra 120 mg (Fexofenadine)
• Allegra 30mg (Fexofenadine)
• Allegra Nasal Duo Spray (Fluticasone / Azelastine)
• Allegra 180 mg (Fexofenadine)
• Okamet 500 Mg (Metformin)
• Framycetin Sulphate Cream (Generic)
• Teicoplanin 400mg (Generic)
• Soframycin Cream (Framycetin Sulphate)